Autore/Fonte: Revue Neurologique
Position paper della French Headache Society sul trattamento dell’emicrania
Read More →
Ottobre 2024
Questo è quello che abbiamo trovato per te
Autore/Fonte: Revue Neurologique
Introduction
Schizophrenia and attention deficit hyperactivity disorder (ADHD) are psychiatric disorders that have a profound impact on patients and healthcare systems globally. There is preliminary evidence suggesting a potential association between the two in terms of symptomatology and genetic underpinning. There is a paucity of guidance regarding pharmacological approaches for patients with comorbid ADHD and schizophrenia. There is a concern that psychostimulants may be more harmful than therapeutic. This scoping review protocol aims to systematically review the evidence for potential harm and benefit of psychostimulants among patients with comorbid ADHD and schizophrenia and identify research gaps.
Methods and analysis
This scoping review will employ a systematic and iterative approach to identify and synthesise the literature on the topic of psychostimulant use among patients with comorbid schizophrenia and ADHD, based on Arksey and O’Malley’s framework. A search will be conducted in relevant databases, including MEDLINE (Ovid), Embase (Ovid), PsycINFO and ISI Web of Science. Additionally, grey literature will be sought. The scoping review will involve two independent reviewers screening the search results. The initial screen will be of title and abstract, and the subsequent full-text review will determine eligibility. A descriptive overview of the eligible studies will be provided. This scoping review has been registered at https://osf.io/cmn5s.
Ethics and dissemination
There is a paucity of high-quality evidence available to clinicians when making decisions regarding the prescription of psychostimulants to patients with comorbid schizophrenia and ADHD. To the best of our knowledge, this will be the first scoping review to examine the evidence addressing this clinical scenario. This review, therefore, has the potential to contribute to decision-making processes for this patient group, thereby improving patient outcomes. Furthermore, as this review is designed to identify research gaps, we aim to contribute to the development of a research agenda that will benefit patients, clinicians and healthcare systems. The dissemination strategy will involve open access peer review publication and scientific presentations.
Non solo un problema dei bimbi ma “attenzione all’autodiagnosi”
Our results suggested that such an imaging-driven, biotype-guided approaches hold promise for facilitating personalized treatment of ADHD and exploring possible boundaries through innovative deep learning algorithms to improve medication treatment effectiveness.
Servizio sanitario regionale 2024 ha assegnato a ASUGI 3,1 mln
Servizio sanitario regionale 2024 ha assegnato a ASUGI 3,1 mln
Autore/Fonte: Josep Carreras Leukaemia Research Institute
Per l’86% degli oncologi sono troppe le disparità di accesso alle cure
Per 86% oncologi sono troppe le disparità di accesso alle cure
Il 22 settembre si celebra la Giornata nazionale di informazione
La ricerca sulla comprensione e sulla gestione di questa malattia neurodegenerativa si apre ai fattori di protezione e allo screening con l’intelligenza artificiale
“Imparare a intercettare i primi segnali, spesso sottovalutati”
Bene lo studio di fase III
Le luci dell’Oms sulla Giornata per la sicurezza del paziente
‘In molti casi otteniamo la guarigione, ma la prevenzione è fondamentale’
Efficace in fase iniziale, con un’accuratezza fino al 98%